CLOSED
GET A PIECE OF IMETABOLIC BIOPHARMA
Show more
Urban Austin Kiernan • Founder, Chairman, CEO, President, and Treasurer
Read More
Stephen Adam Munk • Interim - COO and Board Director
Read More
David F Hendren • Chief Business Officer
Read More
the pitch
At iMBP, we are the next stage of biotech evolution. We are combining innovative technology with biotechnology as part of our proprietary, cutting-edge “TechBio” approach to biopharma. We give communities the opportunity to invest in their own health as we improve the way drugs are discovered to make them more effective and affordable. We have strategic partnerships in place and drug candidates in development in our key markets of metabolic, cardiovascular, and neurodegenerative diseases. The company is pre-revenue and in the prototype phase.
Overview
iMBP is developing a revolutionary approach to drug discovery to help people live longer, healthier, and happier lives with their loved ones. Our founder, Chairman, and CEO Dr. Urban A. Kiernan, Ph.D. is a seasoned BioTech leader with decades of industry business and scientific research experience. However, his passion is what drives him beyond what any academic or work experience could ever afford him.
"The feeling of helplessness I experienced when my first wife died from cancer was devastating. Then, a single Dad with two little girls, the world turned upside-down. From this pain, I recognized the utopic potential the biopharma industry has to offer... and that is the power to keep families together... for just one more... one more memory to hold onto. You cannot put a price tag on that. This is my passion and this is why I created iMBP."
– Dr. Urban A. Kiernan –
Husband, Father, Founder & CEO of iMBP
The Problem & Our solution
Today’s developmental process for new, lifesaving drugs is complex, expensive, and time-consuming. The current industry solution is to simply spend more money, resulting in over-expensive therapeutics with marginal benefits. Ultimately, the deficiencies of this system places the cost burden on the people who need these therapeutic solutions most.
Our Solution was the development of iPlatform™, our proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably. This is the value that TechBio offers to you and your loved ones. Enabled through our partner Amazon Web Services (AWS), iPlatform™ is rapidly evolving and already producing drug asset leads for the expansion of the iMBP drug pipeline.
the market & Our Traction
Our drug asset efforts are currently focused in three primary areas: metabolic disease, cardiovascular disease, and neurodegenerative disease (Alzheimer’s Disease).
Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life, including:
"Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance."
– John Higgins –
CEO at Ligand Pharmaceuticals
Why Invest
Through this raise, we offer communities the opportunity to directly invest in solutions for their own health.
BioTech investment opportunities are typically reserved for an elite circle of the same investors, and we are eager to break this cycle by sharing with you our unique equity crowdfunding campaign.
With major partnerships in place and multiple drug candidates already in development, we are ready to change the way we care for our communities and hope to give loved ones and families as much time together as possible. Invest in iMBP today and become a part of this unique opportunity with us.
A convertible note offers you the right to receive Preferred Stock in iMetabolic BioPharma. The amount of Preferred Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $5,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $25,000,000.00 Valuation Cap or if less, then you will receive a 10.00% discount on the price the new investors are paying. You also receive 3.50% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Preferred Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).
*Annual Interest Rate subject to adjustment based on bonuses below.
Loyalty Bonus | 5% Bonus
As you have previously invested in iMetabolic BioPharma, you are eligible for additional bonus interest.
Time-Based:
Visionary
Invest within the first 72 hours and receive 15% bonus interest.
Disruptor
Invest within the first week and receive 10% bonus interest.
Innovator
Invest within the first two weeks and receive 5% bonus interest.
Amount-Based:
$500+ | Knight
Invest $500+ and receive + 5% bonus interest.
$1,000+ | Baron
Invest $1,000+ and receive + 7% bonus interest.
$5,000+ | Duke
Invest $5,000+ and receive + 10% bonus interest + a Membership to the Exclusive iMBP VIP Forum.
$10,000+ | Prince
Invest $10,000+ and receive + 15% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
$20,000+ | Emperor
Invest $20,000+ and receive + 20% bonus interest + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonuses from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
iMetabolic BioPharma will offer 10% additional bonus interest for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 3.85% instead of 3.5%.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Loyalty Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
12.16.24
During this holiday season, we extend warm wishes to you and your loved ones. As we look back on the past year, we at iMetabolic Biopharma are proud to be at the forefront of a medical revolution.
Our mission is clear: to tackle the growing crisis of obesity-related comorbidities head-on. We're pioneering the future of healthcare with our groundbreaking TechBio AI technology, a tool with the potential to revolutionize the field. This proprietary approach doesn't just enhance the discovery and development of therapeutics—it redefines them.
Your support is crucial as we transform the landscape of medicine, one innovative solution at a time. Visit our website to sign up for our newsletter to follow our developments and latest news. We invite you to follow us on social media to stay informed about our innovative solutions. May your holidays be filled with joy, love, and good health for you and your families.
If you have not been following the company since the close of the campaign, there have been significant advancements made. We have included selected 2024 highlights below.
📢 iMetabolic Biopharma Corporation (iMBP) has received its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH)
We are excited to share that iMetabolic Biopharma Corporation (iMBP) has received its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). This Phase 1 grant, which is funded by the National Heart, Lung, and Blood Institute (NHLBI), will support our innovative drug program aimed at treating atherosclerotic cardiovascular disease (ASCVD), a leading cause of heart attacks and strokes. Our use of the iPlatform™ technology has allowed us to develop a pipeline of promising drug candidates. One of these candidates, the iMBP-001 asset, is a new multidomain recombinant fusion protein that offers unique therapeutic specificity and a novel approach focusing on reducing lipoprotein particles. Dr. Urban Kiernan, our founder and CEO, emphasizes the urgent need for innovative strategies in the treatment of cardiovascular diseases, particularly as the obesity epidemic continues to escalate. Traditional cholesterol-lowering treatments have proven insufficient in tackling this complex issue, which is why we are excited about the potential of our therapeutic innovations, especially with the backing of this NIH grant.
We encourage you to visit Yahoo Finance and read the full press release to delve deeper into our groundbreaking efforts. This ongoing momentum not only enhances the iMBP mission but also positions us as a key player in the investor community.
As we continue to forge new paths, we invite you to join us on this transformative journey that promises to advance health outcomes and create significant value for our stakeholders.
The Decoding Health Podcast with Dr. Urban A. Kiernan
Dr. Kiernan pledged any views of this episode on YouTube to be donated to the Hundley Foundation.
As a part of iMBP’s 2024 outreach campaign, Dr. Kiernan has launched the Decoding Health Podcast which airs new episodes every Monday and Thursday of each week. You may initially question the value of such a media presence however, it allows Dr. Kiernan to highlight science, key team and community members, and participate in cause-based community action. The Decoding Health Podcast was fortunate to have Mr. Brett Hundley in for an interview. A UCLA Bruins superstar who spent 8 seasons in the NFL, Brett has now turned entrepreneur, but more importantly, is the Chairman of the Hundley Foundation. This is a charitable organization to help epilepsy patients and their families. Brett discusses the struggle his family endured and how the creation of the Hundley Foundation can make a positive impact.
Please help by making this episode go viral. This is the easiest donation you will ever do. Just Subscribe to the Decoding Health Podcast, watch the episode (even if only in part), and tell your friends. I hope this episode enhances awareness of this terrible disease.
iMBP in Health and Wellness
Also through the Decoding Health Podcast, Dr. Kiernan has been able to highly his knowledge base and expertise in other industries. He appeared on the IGNITE Coaching Series by Coach360, a premier health and wellness education brand taking the fitness market by storm. With the explosion of the use of Wegovy and Zepbound for weight loss, Dr. Kiernan participated on the IGNITE Coaching Series by Coach360 back in September where he weighed in on the drug’s modes of action, areas of clinical success, and concerns to watch for in the future.
As iMBP’s proprietary multi-domain recombinant fusion protein class of therapeutics have a bioactive mimetic peptide component, Dr. Kiernan is becoming more widely recognized as a leader in the field to provide an unbiased education as to how these new weight loss drugs will impact the health and wellness field as well as society as a whole.
iMBP in the News
We are honored to share that iMBP was featured in the Venture Beat alongside several other inspiring startup companies that are making a difference today.
The VentureBeat is a high-profile investor publication that shows that iMBP is getting noticed. We have also issued our press release formally announcing our second NIH SBIR grant award. Featured in Yahoo Finance, this announcement is being seen by thousands of readers around the world. Again, slowly but surely the iMBP story is building within the investor community. Read the article.
Visit our website to sign up for our monthly newsletter to follow our developments and latest news.
07.07.23
Our sincere thanks to those individuals and groups that have invested in our mission to improve the way drugs are discovered, making them more effective and affordable.
Hear from the founder and CEO of iMBP, Dr. Urban A. Kiernan
Even though our campaign has ended, we want our investors to stay informed. Sign up for updates on the latest iMBP news and events, and see the progress iMBP is making in the biopharma industry!
Thank you!
The iMBP Team
07.06.23
Hello iMBP community!
Time is running out! With just a few hours left, seize the opportunity to invest in iMBP. We are on a mission to be the next stage in developing a revolutionary approach to drug discovery and developing more advanced therapeutic solutions.
Together, we can give communities the opportunity to invest in their own health as we improve how drugs are discovered to make them more effective and affordable.
Only a few hours left to invest Warmest regards,
Dr. Urban A. Kiernan
Found and CEO
iMBP
07.06.23
Hello iMBP community,
Wow, time has flown! Our campaign ends in 24 hours but there’s still time for you to invest in iMBP.
This is your last chance to join the biopharma revolution and make an impact on how drugs are discovered, making them more effective and affordable.
24 hours left to invest - Join the iMBP community by becoming an owner! Thank you,
Dr. Urban A. Kiernan
Found and CEO
iMBP
07.05.23
Hello iMBP supporters,
Don't let this opportunity slip away! iMBP is in its final phase, and you have just 2 days left to invest and become a valued shareholder. Together, we can revolutionize the drug discovery and therapeutics in cardiovascular disease, Alzheimer’s and type 2 diabetes.
Warmest regards,
Dr. Urban A. Kiernan
Found and CEO
iMBP
07.04.23
Dear iMBP Community,
On behalf of the entire iMBP team, allow me to wish each and every one of you who lives in the United States of America a Safe and Happy Independence Day.
Please take this moment to share time with your loved ones and make memories to last a lifetime. You cannot put a price tag on that.
Warmest Regards,
Urban A. Kiernan and the rest of the iMBP Team
07.03.23
iMBP is $50K away from $400K raised! Help us reach our goal and close out our campaign strong.
You have 3 days to invest in a revolutionary company that is pushing boundaries in the biopharma space. For just $250, you can become an early owner!
Our campaign ends in 3 days. Invest today!
Warmest regards,
Dr. Urban A. Kiernan
Found and CEO
07.02.23
Hello iMBP community!
We are in the last few days of our campaign. Here is a message from me spelling out the future direction of iMBP’s fundraising efforts and a personal invitation to all our followers to seize this opportunity while it lasts.
Together, we can make a difference in improving the treatment of disease. So, what are you waiting for? – join the community by becoming an owner!
Thank you,
Dr. Urban A. Kiernan
Found and CEO
06.30.23
Hello iMBP community!
We have 6 days left of our crowdfunding campaign.
WOW! Where did the time go? This year would not have been possible without amazing investors like you!
There are 6 days left of our crowdfunding campaign, and you can become an investor in iMBP for only $250. We are entering a brand-new era of revolutionizing the biopharma space!
We hope you'll join us on this journey! If you want to help us complete this extraordinary campaign, now is the time!
Please share our raising page with your network, encourage them to invest, and help transform the drug discovery process.
Dr. Urban A. Kiernan
Founder and CEO
06.29.23
There are just 7 DAYS left to become an official part-owner in the biopharma revolution.
Here at iMBP, we are on a mission to develop new, life-saving drugs to fight against Alzheimer’s disease, cardiovascular disease and type 2 diabetes.
Our campaign is closing in 1 week. Invest before the campaign ends!
Warmest regards,
Dr. Urban A. Kiernan
Found and CEO
iMBP
Members get an extra 10% interest rate in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus interest rate on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Knight
Invest $500+ and receive + 5% Bonus.
Baron
Invest $1,000+ and receive + 7% Bonus.
Duke
Invest $5,000+ and receive + 10% Bonus + a Membership to the Exclusive iMBP VIP Forum.
Prince
Invest $10,000+ and receive + 15% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
Emperor
Invest $20,000+ and receive + 20% Bonus + a Membership to the Exclusive iMBP VIP Investor Club + complimentary access for you and a guest to a future iMBP sponsored event in Arizona.
0/2500
iMetabolic BioPharma
•
2 years ago
Show more
0
0
2 years ago
Show more
1
1
2 years ago
Show more
1
0
2 years ago
Show more
1
0
2 years ago
1
0
2 years ago
Show more
1
0
2 years ago
2
0
2 years ago
Show more
1
0
2 years ago
Show more
1
0
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Jarod Rudisill
5 months ago
Hi, I have received zero updates since investing. Would love an update. I'm sure all other investors would like one as well.
Show more
1
0